Baltimore, Maryland / January 23, 2014 / Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that with the announcement of its recent license agreement with Diego Pellicer, Inc. and Diego Pellicer Worldwide Inc., Planda Biotechnology, Inc. (OTCQB –PLPL) has positioned itself at the head of the class in the medical marijuana industry. The license enables Planda to use the Diego Pellicer name for its Phytofare(TM) cannabis extracts in medical and pharmaceutical marijuana applications. Tracing its roots back over one hundred years, the Diego Pellicer name and legacy represents the Rolls Royce of brands in the cannabis industry.
According to senior analyst Rob Goldman, “For Planda, being able to sell its cannabinoid extracts under the Diego Pellicer moniker will bring tremendous name recognition, branding, and a highly respected status in the medicinal cannabis industry. Moreover, this partnership validates the Company’s Phytofare(TM) technology, bioavailability and approach to medical marijuana. Clearly, both companies believe this one-two punch will prompt users to be drawn to what could emerge as a leading offering in the space. This outlook is based upon the combination of the power of the Diego Pellicer brand and the Planda product’s high bioavailability, which will result in lower dosages and lower costs.”
Goldman also believes that the news could not come at a better time for Planda and its shareholders. In recent days, President Obama has tacitly endorsed the use of marijuana by noting that it is less dangerous than alcohol. Moreover, proponents of medical marijuana will likely use the 2-week Super Bowl marketing period to flood the media with stories on the topic, placing it near the top of the talking points food chain, since the two Super Bowl representatives are from the two states that have legalized marijuana. Legislators and citizens of cash-strapped states and municipalities may view a softening stance on this topic as tangible opportunity to generate real revenue.
“These events have clearly placed medical marijuana front and center as a strong, new investment category, as well as at the top of the list of discussions be legislators and consumers alike. As a result, investors should expect that medical marijuana companies and their stocks will remain under accumulation for the foreseeable future,” commented Goldman.
This press release contains excerpts of our most recently published article on Planda. Goldman Small Cap Research sponsored articles, reports, and updates on Plandai as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting http://www.goldmanresearch.com/.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit http://www.goldmanresearch.com/.
About Plandai Biotechnology, Inc. (OTCQB – PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout. Targeted industries for the Company’s products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.
For more information, please visit http://www.plandaibiotech.com/
Goldman Small Cap Research
Rob Goldman, Analyst
Source: Goldman Small Cap Research